Search - tctmd.com

Displaying 141 - 160 of 389

Sort: Relevancy | Date

LAACS: Surgical Closure of the Left Atrial Appendage Shows Promise

News Conference News ESC 2017

LAACS: Surgical Closure of the Left Atrial Appendage Shows Promise

September 04, 2017

Clinical Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

News Conference News ESC 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Michael O'Riordan

August 31, 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

News Conference News ESC 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

August 30, 2017

Under Pressure: PRECISION Substudy Shows Adverse BP Effects of Ibuprofen

News Conference News ESC 2017

Under Pressure: PRECISION Substudy Shows Adverse BP Effects of Ibuprofen

August 30, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

News Conference News ESC 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Michael O'Riordan

August 29, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

August 26, 2017

After Failed Mitral Valve Surgery, Transcatheter Valve-in-Valve or Valve-in-Ring Shows Promise in High-Risk Patients

News Daily News

After Failed Mitral Valve Surgery, Transcatheter Valve-in-Valve or Valve-in-Ring Shows Promise in High-Risk Patients

Yael L. Maxwell

August 24, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

Episode 28: The AMULET Observational Study

Podcast TCTMD Talking Points

Episode 28: The AMULET Observational Study

August 23, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Off-Pump CABG Linked to Higher Long-term Mortality in ROOBY

News Daily News

Off-Pump CABG Linked to Higher Long-term Mortality in ROOBY-FS

August 16, 2017

Five-Year Outcomes After On-Pump and Off-Pump Coronary-Artery Bypass

Presentation

Five-Year Outcomes After On-Pump and Off-Pump Coronary-Artery Bypass

August 16, 2017

Episode 27: The WATCHMAN US Postapproval Study

Podcast TCTMD Talking Points

Episode 27: The WATCHMAN US Postapproval Study

August 16, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.